Hot Products

Immortalized Mouse Dopaminergic Neuronal Cells (MN9D)

Cat.No.: CSC-I2295Z

Species: mouse

Morphology: Polygonal

Culture Properties: Adherent

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-I2295Z
Description
Immortalized Mouse Dopaminergic Neuronal Cell line (MN9D) was generated by fusion between rostral mesencephalic neurons from a 14-day-old C57BL/6J mouse embryo and N18TG2 neuroblastoma cells, a sympathetic nervous system cancer of A/Jax background. MN9D cells produce dopamine (DA) and express tyrosine hydroxylase (TH) as well as aromatic amino acid decarboxylase (AADC). MN9D cells readily aggregate with one another or other embryonic brain cells and can be transfected using calcium phosphate precipitation or Lipofectamine. Undifferentiated or differentiated MN9D cells are extensively used to model dopaminergic neurons and to test mechanisms and potential therapeutics relevant to the loss of DA neurons in Parkinson's disease. Differentiated with butyric acid or glial cell line-derived neurotrophic factor (GDNF) followed by butyric acid, MN9D cells only partially recapitulate the electrophysiological properties of midbrain DA neurons. Optimizing MN9D differentiation further using one or a combination of growth or other factors may yield an improved model system for Parkinson's disease studies in vitro.
Species
mouse
Recommended Medium
SuperCult® Immortalized Mouse Dopaminergic Neuronal Cell Medium (Cat No.: CM-I2295Z)
Freezing Medium
Complete medium supplemented with 10% (v/v) DMSO
Culture Properties
Adherent
Morphology
Polygonal
Application
For Research Use Only
Growth Properties
Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO2.
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

MN9D is an immortalized murine dopaminergic neuronal cell line created by somatic cell fusion of dopamine neurons from mouse embryonic ventral midbrain with neuroblastoma cells (N18TG2). Morphologically, they are immature neurons, but when cultured in special conditions can be induced to extend neurites and differentiate (e.g. by treatment with all-trans retinoic acid (tRA)). Although they appear as immature neurons morphologically these cells show dopaminergic differentiation features like tyrosine hydroxylase (TH) expression and dopamine production capacity under appropriate conditions.

MN9D cells express dopamine and related enzymes which makes them useful for creating dopaminergic neuron injury models including neurodegeneration models for diseases like Parkinson's. MN9D cells are also commonly used to study the neurotoxic effects of various neurotoxic compounds (such as 6-hydroxydopamine (6-OHDA), MPP+, etc.) on dopaminergic neurons, as well as the protective effects of antioxidants and other neuroprotectants.

Immortalized HPMEC cultures generated through co-transfection with hTERT and SV40 large T antigen plasmids.Fig. 1. Morphological characteristics of MN9D cells (Tian P X, Shi W B, et al., 2015).

Effects of Propofol alone or Combined with Curcumin on the Cell Viability of MN9D Cells

Propofol abuse can cause neurotoxicity and cognitive deficits. Autophagy dysregulation contributes to neuronal injury. Curcumin is a natural polyphenol derived from the turmeric plant, and it has neuroprotective and cognition-enhancing properties. He's team investigated whether curcumin protects MN9D dopaminergic cells against propofol-induced neurotoxicity by modulating autophagy via the Akt/mTOR/p70S6K signaling pathway.

They first evaluated MN9D cell cytotoxicity using CCK-8 assays. Methanol was used as a solvent and a negative control due to the hydrophobicity of curcumin. Cells were treated with 1-80 μM curcumin or 5-80 μg/mL propofol for 24 h (Fig.1c and d). Curcumin had low toxicity, even at 80 μM. Propofol was dose-dependently cytotoxic (viability was reduced to about 80% at 40 μg/mL) and decreased cell density. Therefore, 40 μg/mL propofol was used with 10-40 μM curcumin to explore neuroprotection (Fig. 1e and f). After 24 h, propofol-treated cells were smaller in size with decreased nodules, but curcumin co-treated cells had an almost 90% viability and exhibited protection from propofol-induced senescence with spindle-like morphology.

Propofol-induced suppression of MN9D cell proliferation and curcumin-mediated rescue.Fig. 1. Impact of propofol alone or in combination with curcumin on MN9D cell growth (He H X, Han Y P, et al., 2024).

Rotenone and Antimycin A Significantly Reduced ATP Production and Disrupt Catecholamine Biosynthesis in MN9D Cells

Mitochondrial dysfunction is central to Parkinson's disease (PD), as dopaminergic neurons are highly susceptible to oxidative stress and energy depletion. Rotenone (Complex I inhibitor) and antimycin A (Complex III inhibitor) disrupt mitochondrial function, but their comparative effects on dopaminergic neurons remain unclear.

Adetuyi et al. investigated how rotenone and antimycin A induce energy depletion, oxidative stress, and neuronal death in MN9D dopaminergic cells to elucidate their roles in PD pathogenesis. Figure 2 demonstrates ATP levels in MN9D cells treated with mitochondrial toxins. Cells exposed to rotenone (1.5 µM) or antimycin A (10 µM) for 1 hour showed significantly reduced ATP production compared to control (KRB-HEPES buffer, pH 7.5), measured via colorimetric/fluorometric assays. To assess catecholamine biosynthesis, cells were treated with rotenone (1.5 µM), antimycin A (10 µM), or tetrabenazine (1 µM) for 1 hour. Figure 3a-c reveals that all three toxins markedly decreased dopamine levels versus control, as quantified by HPLC.

Mitochondrial toxin exposure depletes cellular ATP levels.Fig. 2. Effect of Toxins treatment on ATP level (Adetuyi OA, Wimalasena K, et al., 2025).

Rotenone and antimycin A impair dopaminergic biosynthesis pathways.Fig. 3. Rotenone and Antimycin A disrupt catecholamine biosynthesis (Adetuyi OA, Wimalasena K, et al., 2025).

Ask a Question

Write your own review

For research use only. Not for any other purpose.